1169 / 1498
•
Single agent rituximab in previously untreated patients
overall response rates: 50-87%
median time to disease progression <1 year
Treatment
Immunotherapy
Conconi et al. 2003; Ferreri et al. 2005; Benetatos et al. 2006; Heinz et al. 2007
•
90Y ibritumomab tiuxetan for front line treatment of stage IE
indolent OAL in 12 patients:
complete response in 10 patients
partial response in 2 patients
Esmaeili et al. 2009; Shome and Esmaeili 2008